HD-derived anti-BCMA CAR T cells efficiently targeted multiple myeloma primary cells in a dose–response manner as shown in the representative example (Fig. 4D), with 52.5% cell lysis of MM#16 at an E:T ratio of 10:1 compared with 2.8% lysis using UT cells from the same donor. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.